1. Home
  2. SRPT vs PBMWW Comparison

SRPT vs PBMWW Comparison

Compare SRPT & PBMWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRPT
  • PBMWW
  • Stock Information
  • Founded
  • SRPT 1980
  • PBMWW N/A
  • Country
  • SRPT United States
  • PBMWW Canada
  • Employees
  • SRPT N/A
  • PBMWW 10
  • Industry
  • SRPT Biotechnology: Pharmaceutical Preparations
  • PBMWW
  • Sector
  • SRPT Health Care
  • PBMWW
  • Exchange
  • SRPT Nasdaq
  • PBMWW Nasdaq
  • Market Cap
  • SRPT N/A
  • PBMWW N/A
  • IPO Year
  • SRPT 1997
  • PBMWW N/A
  • Fundamental
  • Price
  • SRPT $107.95
  • PBMWW $0.02
  • Analyst Decision
  • SRPT Buy
  • PBMWW
  • Analyst Count
  • SRPT 22
  • PBMWW 0
  • Target Price
  • SRPT $174.64
  • PBMWW N/A
  • AVG Volume (30 Days)
  • SRPT 799.4K
  • PBMWW N/A
  • Earning Date
  • SRPT 02-26-2025
  • PBMWW N/A
  • Dividend Yield
  • SRPT N/A
  • PBMWW N/A
  • EPS Growth
  • SRPT N/A
  • PBMWW N/A
  • EPS
  • SRPT 1.22
  • PBMWW N/A
  • Revenue
  • SRPT $1,640,348,000.00
  • PBMWW N/A
  • Revenue This Year
  • SRPT $53.06
  • PBMWW N/A
  • Revenue Next Year
  • SRPT $68.79
  • PBMWW N/A
  • P/E Ratio
  • SRPT $88.50
  • PBMWW N/A
  • Revenue Growth
  • SRPT 48.45
  • PBMWW N/A
  • 52 Week Low
  • SRPT $102.16
  • PBMWW N/A
  • 52 Week High
  • SRPT $173.25
  • PBMWW N/A
  • Technical
  • Relative Strength Index (RSI)
  • SRPT 33.84
  • PBMWW N/A
  • Support Level
  • SRPT $109.52
  • PBMWW N/A
  • Resistance Level
  • SRPT $114.41
  • PBMWW N/A
  • Average True Range (ATR)
  • SRPT 3.36
  • PBMWW 0.00
  • MACD
  • SRPT -0.50
  • PBMWW 0.00
  • Stochastic Oscillator
  • SRPT 2.73
  • PBMWW 0.00

About PBMWW Psyence Biomedical Ltd. Warrant

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Share on Social Networks: